Three years of imatinib is considered the standard duration of adjuvant therapy for patients with operable high-risk gastrointestinal stromal tumours (GIST).
Despite this, many patients remain at high risk of recurrence after completing three years of adjuvant imatinib treatment. The aim of the SSGXXII trial is to compare the effect of giving imatinib for 5 years versus 3 years in patients who have undergone surgery for high-risk GIST.
The study aims to recruit 300 patients globally by the end of September 2022. Eligible patients will visit recruiting sites around Australia:
- Royal North Shore Hospital (NSW)
- Lake Macquarie Private hospital (NSW)
- Peter Macallum Cancer Centre (VIC)
- The Alfred Hospital (VIC)
- Peninsula South Eastern Haematology & Oncology Group (VIC)
- Royal Brisbane & Women’s hospital (QLD)
- The Queen Elizabeth Hospital (SA)
- Fiona Stanley Hospital (WA)
Regional, rural, or remote patients will also be considered for enrolment, as many of the study visits can be performed via telehealth.
More details about the trial and eligibility criteria are available on the ANZCTR website.